Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study
European Journal of Cancer2015Vol. 51(12), pp. 1497–1510
Citations Over TimeTop 10% of 2015 papers
Lotte E. Elshof, Konstantinos Tryfonidis, Leen Slaets, A. Elise van Leeuwen‐Stok, Victoria Skinner, Nicolas Dif, Ruud M. Pijnappel, Nina Bijker, Emiel J. Rutgers, Jelle Wesseling
Related Papers
- → Modeling the natural history of ductal carcinoma in situ based on population data(2020)42 cited
- → Digital mammography screening: Weighing reduced mortality against increased overdiagnosis(2011)55 cited
- → Does Localized Prostate Cancer Exist?(2007)4 cited
- → Overtreatment in surgery – does it concern also the patients with ductal breast carcinoma in situ(2018)3 cited
- → The successful patient-preference design for the LORD-trial to test whether active surveillance for low-risk Ductal Carcinoma In Situ is safe(2022)